Dual Diagnosis in Patients with Schizophrenia: Issues in Pharmacological Treatment

CNS Drugs

Volumn 5, Issue 6, 1996, Pages 414-425

  Soyka, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; ALPRAZOLAM; AMANTADINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZATROPINE; BENZODIAZEPINE; BIPERIDEN; BROMOCRIPTINE; CANNABIS; CARBAMAZEPINE; CLOZAPINE; COCAINE; DESIPRAMINE; DIAZEPAM; DISULFIRAM; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; METHADONE; NALTREXONE; NEUROLEPTIC AGENT; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; TIAPRIDE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

AGRANULOCYTOSIS; DETOXIFICATION; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; TARDIVE DYSKINESIA;

EID: 0029995515     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605060-00002     Document Type: Article

References (107)

1. Siris SG, Docherty JP. Psychosocial management of substance abuse in schizophrenia. In: Herz MI, Keith SJ, Docherty JP, editors. Handbook of schizophrenia. Vol. 4: Psychosocial treatment of schizophrenia. Amsterdam: Elsevier, 1990: 339-54
2. Kofoed L, Kania J, Walsh T, et al. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 1986; 143: 867-72
3. Hellerstein DJ, Meehan B. Outpatient group therapy of schizophrenic substance abusers. Am J Psychiatry 1987; 119: 106-15
4. Minkoff K. An integrated treatment model for dual diagnosis of psychosis and addiction. Hosp Commun Psychiatry 1989; 40: 1031-40
5. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol 1992; 60: 845-56
6. Helzer JD, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988; 49: 219-24
7. Soyka M, Albus M, Finelli A, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 1993; 242: 362-72
8. Alterman AI, Erdlen DL, Laporte DJ, et al. Effects of illicit drug use in an inpatient psychiatric population. Addict Behav 1982; 7: 231-42
9. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry 1994; 165: 13-21
10. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis 1987; 75: 641-52
11. Cuffel BJ. Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 1992; 180: 589-93
12. Alterman AI. Methodological issues and prevalence estimates of substance abuse in schizophrenia [commentary]. J Nerv Ment Dis 1992; 180: 593-4
13. Siris SG. Substance abuse in schizophrenia [commentary]. J Nerv Ment Dis 1992; 180: 595-6
14. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224-30
15. Carey MP, Carey KB, Meisler AW. Psychiatric symptoms in mentally ill chemical abusers. J Nerv Ment Dis 1991; 179: 136-8
16. Carpenter MD, Mulligan JC, Bader IA. Multiple admissions to an urban psychiatric center: a comparative study. Hosp Community Psychiatry 1985; 36: 1305-8
17. Crowley TJ, Chesluk D, Dilts S, et al. Drug and alcohol abuse among psychiatric admissions. Arch Gen Psychiatry 1974; 95: 13-20
18. Safer DJ. Substance abuse by young adult chronic patients. Hosp Community Psychiatry 1987; 38: 511-4
19. Miller FT, Tanenbaum JH. Substance abuse in schizophrenia. Hosp Commun Psychiatry 1989; 40: 847-9
20. Drake RE, Wallach MA. Mental patients' attitudes toward hospitalization: a neglected aspect of hospital tenure. Am J Psychiatry 1988; 145: 29-34
21. Bartels SJ, Drake RE, Wallach MA, et al. Characteristic hostility in schizophrenic outpatients. Schizophr Bull 1991; 17: 163-71
22. Soyka M. Alcohol and drug abuse as risk factor for delinquency and violent behavior in schizophrenic patients - how strong is the evidence?. J Clin For Med 1994; 1: 3-7
23. Dixon L, Haas G, Weiden P, et al. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 1990; 16: 69-79
24. Test MA, Wallisch LS, Allness DJ, et al. Substance abuse in young adults with schizophrenic disorders. Schizophr Bull 1989; 15: 465-76
25. Sherer MA, Kumor KM, Cone EJ, et al. Suspiciousness induced by four-hour intravenous infusions of cocaine. Arch Gen Psychiatry 1988; 45: 673-7
26. Cesarec Z, Nyman AK. Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 1985; 71: 523-38
27. van Kammen DP, Bunney WE, Docherty JP, et al. d-Amphetamine-induced heterogenous changes in psychotic behavior in schizophrenia. Am J Psychiatry 1982; 139: 991-7
28. Kornetzsky C. Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch Gen Psychiatry 1976; 33: 1425-8
29. van Kammen DP, Boronow JL. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int J Clin Psychopharmacol 1988; 3: 111-21
30. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987; 44: 286-95
31. Lieberman JA, Kane MJ, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91: 415-33
32. Carpenter MD, Winsberg BG, Camus LA. Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol 1992; 12: 273-5
33. Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 1984; 20 (3): 572-84
34. Gawin FH. Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology 1986; 90: 142-3
35. Knudsen P, Vilmar T. Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr Scand 1984; 69: 162-74
36. Seibyl JP, Satel SL, Anthony D et al. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 1993; 181: 31-7
37. Bowers MB, Mazure CM, Nelson JC, et al. Psychogenetic drug use and neuroleptic response. Schizophr Bull 1990; 16: 81-5
38. Forrest FM, Forrest IS, Finkle BS. Alcohol-chlorpromazine interaction in psychiatric patients. Aggressologie 1971; 13: 67-74
39. Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 1991; 84: 272-6
40. Soni SD, Bamrah JS, Krska J. Effects of alcohol on serum fluphenazine levels in stable chronic schizophrenics. Hum Psychopharmacol 1991; 6: 301-6
41. Siris SG. Pharmacological treatment of substance-abusing schizophrenic-patients. Schizophr Bull 1990; 16: 111-22
42. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine and levamfetamine: effects on schizophrenic symptoms. Arch Gen Psychiatry 1976; 33: 304-8
43. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985; 46: 79-83
44. Kosten TR. Kleber HD. Rapid death during cocaine abuse: variant of the neuroleptic treatment malignant syndrome? Am J Drug Alcohol Abuse 1988; 14: 335-46
45. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance abuse. Am J Alcohol Abuse 1990; 16: 57-66
46. Duke PJ, Pantelis C, Barnes TRE. South Westminster Schizophrenia Survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994; 164: 630-6
47. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33: 121-2
48. Zaretsky A, Rector NA, Seeman MV, et al. Current cannabis use and tardive dyskinesia. Schizophr Res 1993; 11: 3-8
49. Moeller HJ, von Zersen S, Depressive states during the neuroleptic treatment of schizophrenia. Schizophr Bull 1982; 8: 109-17
50. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991; 17: 75-98
51. Van Putten T, May RP. 'Akinetic depression' in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101-7
52. Bandelow B, Müller P, Frick U, et al. Depressive syndromes in schizophrenic patients under neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci 1992; 241: 291-5
53. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry 1990; 157: 25-34
54. Barmah JS, Kumar V, Kraska J, et al. Interaction between procyclidine and neuroleptic drugs: some pharmacological and clinical aspects. Br J Psychiatry 1986; 149: 726-33
55. Johnstone EC, Crow TJ, Ferrier IN, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13: 513-27
56. Jellinek T. Mood elevating effect of trihexyphenidyl and hiperiden in individuals taking antipsychotic medication. Dis Nerv Syst 1977; 38: 353-5
57. MacVicar K. Abuse of antiparkinsonian drugs by psychiatric patients. Am J Psychiatry 1977; 134: 809-11
58. Pullen GP, Best NR, Maguire J. Anticholinergic drug abuse: a common problem? BMJ 1984; 289: 612-3
59. Fisch RZ. Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatr Scand 1987; 75: 91-4
60. Smith JM. Abuse of antiparkinsonian drugs: a review of the literature. J Clin Psychiatry 1980; 41: 351-4
61. Buckley P, Thompson PA, Way L, et al. Substance abuse and clozapine treatment. J Clin Psychiatry 1994; 55 (9 Suppl. B): 114-6
62. Myers RD, Lankford M, Bjork A. Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacol Biochem Behav 1992; 43: 661-7
63. McMillen BA, Jones EA, Hill LJ, et al. Amperozide, a 5-HT2 antagonist, attenuates craving for cocaine by rats. Pharmacol Biochem Behav 1993; 46: 125-9
64. Siris SG, Bermanzohn PC, Mason SE, et al. Antidepressants for substance-abusing schizophrenic patients: a minireview. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 1-13
65. Siris SG, Mason SE, Bermanzohn PC, et al. Dual diagnosis/psychiatric comorbidity of drug dependence: epidemiology and treatment. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993; 29: 127-33
66. Siris SG, Kane JM, Frechen K, et al. Histories of substance abuse in patients with postpsychotic depressions. Compr Psychiatry 1988; 29: 550-7
67. Fischman MW, Foltin RW, Nestadt G, et al. Effects of desipramine maintenance on cocaine self-administration by humans. J Pharm Exp Ther 1990; 253: 760-70
68. Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989; 46: 117-21
69. Kosten TR, Gawin FH, Kosten TA, et al. Six-month follow-up of short-term pharmacotherapy for cocaine dependence. Am J Addictions 1992; 1: 40-9
70. Kosten TR. Pharmacotherapeutic interventions for cocaine abuse: matching patients to treatments. J Nerv Ment Dis 1989; 177: 379-89
71. Carroll KM, Nich C, Rounsaville BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J Nerv Ment Dis 1995; 183: 251-9
72. Siris SG, Bermanzohn PC, Mason SE, et al. Maintenance imipramine therapy for secondary depression in schizophrenia. Arch Gen Psychiatry 1994; 51: 109-15
73. Hudson CJ. Tricyclic antidepressants and alcoholic blackouts. J Nerv Ment Dis 1981; 169: 381-2
74. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714-26
75. Wolkowitz OM, Breier A, Doran A, et al. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Arch Gen Psychiatry 1988; 45: 664-71
76. Kahn JP, Puertollano MA, Schane MD, et al. Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. Am J Psychiatry 1988; 145: 742-4
77. Dixon L, Weiden PJ, Frances AJ, et al. Alprazolam intolerance in stable schizophrenic outpatients. Psychopharmacol Bull 1989; 25: 213-4
78. Levi-Minzi S, Bermanzohn PC, Siris SG. Bromocriptine for 'negative' schizophrenia. Compr Psychiatry 1991; 32: 210-6
79. Borg V, Weinholdt T. Bromocriptine in the treatment of alcohol-withdrawal syndrome. Acta Psychiatr Scand 1982; 65: 101-11
80. Borg V. Bromocriptine in the prevention of alcohol abuse. Acta Psychiatr Scand 1983; 68: 100-10
81. Pollack MH, Brotman AW, Rosenbaum JF. Cocaine abuse and treatment. Compr Psychiatry 1989; 30: 31-44
82. Roberts DCS, Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioral screen for antipsychotic activity. Psychopharmacology 1984; 82: 135-9
83. Herz A. Neurobiologische Grundlagen des Suchtgeschehens. Nervenarzt 1995; 66: 3-14
84. Spealman RD, Bergman J, Madras BK, et al. Role of D1 and D2 dopamine receptors in the behavioral effects of cocaine. Neurochem Int 1992; 20 Suppl.: 147S-52S
85. Spealman RD, Bergman J, Madras BK, et al. Discriminative stimulus of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther 1991; 258: 945-53
86. Spealman RD. Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology 1990; 101: 142-5
87. Gawin FH, Allen D, Humblestone B. Outpatient treatment of 'crack' cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 1989; 46: 322-5
88. Mansbach RS, Jortani SA, Balster RL. Antagonism of cocaine's reinforcing and discriminative stimulus effects by alpha-flupenthixol. Exp Clin Psychopharmacol 1994; 2: 3-12
89. Soyka M, Sand P. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry 1995; 28: 64-5
90. Schilkrut R, Cabrera J, Morales E, et al. Neuroleptics in the treatment of drug dependence in schizophrenics: a study with flupenthixol decanoate [abstract no. 33.01.50]. Psychopharmacology 1988; 96 Suppl.: 342
91. O'Malley SS, Jaffe AJ, Chung G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992; 49: 881-7
92. Volpicelli JR, Alterman AI. Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80
93. Brizer DA, Hartman N, Sweeney J, et al. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 1985; 142: 1106-7
94. Judd LL, Janowsky DS, Segal DS, et al. Behavioral effects of methadone in schizophrenic patients. Am J Psychiatry 1981; 138: 243-5
95. Ewing JA, Meuller RA, Rouse BA, et al. Low levels of dopamine beta-hydroxylase and psychosis. Am J Psychiatry 1977; 134: 927-8
96. Major LF, Lerner P, Ballenger JC, et al. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 1979; 14: 337-44
97. Feuerlein W. Alkoholismus - Mißbrauch und Abhängigkeit. 4. Auflage. Stuttgart: Thieme, 1989
98. Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism: an evaluation in 128 men. Ann Intern Med 1979; 90: 901-4
99. Kofoed L. Chemical monitoring of disulfiram compliance: a study of alcoholic outpatients. Alcohol Clin Exp Res 1987; 11: 481-5
100. Osher FL, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance abuse disorder. Hosp Community Psychiatr 1989; 90: 1025-30
101. Soyka M. Die Alkoholkrankheit - Diagnostik und Therapie. Weinheim: Chapman & Hall, 1995
102. Soyka M. Psychotherapy and pharmacotherapy for the treatment of alcoholism in Germany. Alcohol Drug Depend 1995; 39: S9-S13
103. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo-controlled study in alcohol dependence. Arch Gen Psychiatry. In press
104. Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Berlin: Springer. In press
105. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention. Am J Psychiatry 1995; 152: 391-7
106. Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47: 1010-47
107. Selzer JA, Lieberman JA. Schizophrenia and substance abuse. Psychiatr Clin North Am 1993; 116: 401-12